CSBio CSBio

X
[{"orgOrder":0,"company":"CureVac","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$34.0 million","upfrontCash":"$8.3 million","newsHeadline":"CureVac and CEPI extend their Cooperation to Develop a Vaccine against Coronavirus nCoV-2019","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Vaccine","productStatus":"Undisclosed","date":"January 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"CureVac"},{"orgOrder":0,"company":"BioNTech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","amount":"$180.0 million ","upfrontCash":"$135.0 million ","newsHeadline":"BioNTech and Fosun to Develop mRNA Vaccine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"BioNTech"},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech reports rapid progress on COVID-19 vaccine program to address global public health threat","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"BioNTech"},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac\u00b4s Optimized mRNA Platform Provides Positive Pre-Clinical Results at Low Dose for Coronavirus Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"CureVac"},{"orgOrder":0,"company":"IgNova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IgNova Files Patent Application on Antibody Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"IgNova"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laboratory Studies Confirm BETADINE(R) Antiseptic Products' Effectiveness Against COVID-19 Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Mundipharma"},{"orgOrder":0,"company":"CureVac","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$147.1 million","newsHeadline":"GSK and CureVac Announce Strategic mRNA Technology Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"CureVac"},{"orgOrder":0,"company":"DiosCURE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DiosCURE to Develop Highly Specific Single-Chain Antibodies Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"DiosCURE Therapeutics"},{"orgOrder":0,"company":"CureVac","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"CureVac"},{"orgOrder":0,"company":"MolGenie","sponsor":"OntoChem","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OntoChem Assigns Anixa Covid-19 Drug Discovery Project to MolGenie","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"MolGenie"},{"orgOrder":0,"company":"Innovative Molecules","sponsor":"Life Sciences Partners","pharmaFlowCategory":"D","amount":"$23.7 million","upfrontCash":"Undisclosed","newsHeadline":"Innovative Molecules Raises \u20ac20 Million Series A Equity Financing Round","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Innovative Molecules"},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$425.0 million","upfrontCash":"$225.0 million","newsHeadline":"Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"BioNTech"},{"orgOrder":0,"company":"Ethris","sponsor":"Laureus Capital","pharmaFlowCategory":"D","amount":"$26.3 million","upfrontCash":"Undisclosed","newsHeadline":"Ethris Raises $26.3 Million Series B to Advance Pipeline of mRNA-based Therapeutics for Respiratory Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Ethris"},{"orgOrder":0,"company":"Cevec","sponsor":"Rokote Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rokote Laboratories Licenses Cevec\u2019s Cap\u00ae Ad Technology For Vaccine Manufacturing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Cevec"},{"orgOrder":0,"company":"Ethris","sponsor":"DIOSynVax","pharmaFlowCategory":"D","amount":"$42.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ethris Announces Collaboration with DIOSynVax and CEPI to Develop a Broadly Protective mRNA Vaccine Against Betacoronaviruses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Ethris"},{"orgOrder":0,"company":"Smartbax","sponsor":"Boehringer Ingelheim Venture Fund","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"smartbax Announces Seed Financing of \u20ac1.2 Million to Develop Next-generation Antibiotics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Smartbax"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The funds will be used to advance smartbax’s small molecule antibiotics through preclinical studies, expand the company’s scientific team to further develop its innovative research platforms and identify novel solutions against multi-drug resistant pathogens.

            Lead Product(s): Undisclosed

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Boehringer Ingelheim Venture Fund

            Deal Size: $1.2 million Upfront Cash: Undisclosed

            Deal Type: Financing May 23, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Ethris will design and manufacture the mRNA vaccine candidate containing DIOSynVax’s broadly protective, multi-virus vaccine antigen payload designs. This vaccine approach aims to provide protection from SARS-CoV-2 - the virus which causes COVID-19 disease.

            Lead Product(s): mRNA-based Covid-19 Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: DIOSynVax

            Deal Size: $42.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration December 21, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, CEVEC has granted ROKOTE a non-exclusive rights to use the CAP® Ad platform for the manufacturing of adeno-based vaccines (FINCoVac 2.1) for prophylactic and therapeutic use in infectious diseases such as COVID-19, influenza and RSV infections.

            Lead Product(s): FINCoVac 2.1

            Therapeutic Area: Infections and Infectious Diseases Product Name: FINCoVac 2.1

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Rokote Laboratories

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement September 20, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The proceeds will advance the company’s lead programs ETH47 and ETH42, into clinical studies, further advance its proprietary and differentiated mRNA and lipidoid nanoparticle delivery platforms and increase its manufacturing capabilities.

            Lead Product(s): ETH47

            Therapeutic Area: Infections and Infectious Diseases Product Name: ETH47

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Laureus Capital

            Deal Size: $26.3 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing February 01, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The companies will leverage Pfizer's proprietary antigen technology and BioNTech's proprietary mRNA platform to develop mRNA based vaccine for Shingles. Pfizer will have rights to commercialize the vaccine gobally, except Germany, Turkey and certain developing countries.

            Lead Product(s): mRNA-based Shingles Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Pfizer Inc

            Deal Size: $425.0 million Upfront Cash: $225.0 million

            Deal Type: Collaboration January 05, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The company will use the funds to advance its preclinical product candidate, IM-250, from the current late preclinical stage to a Phase 2 proof-of-concept study. IM-250 is a potent inhibitor of Herpes Simplex Virus type 1 (HSV-1) and type 2 (HSV-2) replication.

            Lead Product(s): IM-250

            Therapeutic Area: Infections and Infectious Diseases Product Name: IM-250

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Life Sciences Partners

            Deal Size: $23.7 million Upfront Cash: Undisclosed

            Deal Type: Series A financing June 07, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Preclinical data in rats immunized with CV2CoV in the dose range of 0.5-40µg demonstrated fast onset of strong immune responses already after the first dose.

            Lead Product(s): CV2CoV

            Therapeutic Area: Infections and Infectious Diseases Product Name: CV2CoV

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: GSK

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 13, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Anixa and OntoChem were seeking to develop an orally administrable, metabolically stable, non-toxic anti-viral therapy against SARS-CoV-2, the virus that causes Covid-19. Anixa is now working with MolGenie to use the generated compounds and data.

            Lead Product(s): Undisclosed

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: OntoChem

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 07, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Preclinical studies demonstrated that DIOS-202 and DIOS-203 selectively target two distinct epitopes of the SARS-CoV-2 spike protein at once, which largely prevents the emergence of escape mutants.

            Lead Product(s): DIOS-202,DIOS-203

            Therapeutic Area: Infections and Infectious Diseases Product Name: DIOS-202

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 12, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, GSK will fund R&D activities at CureVac related to the development projects covered by the collaboration and CureVac will be responsible for the preclinical- and clinical development through Phase 1 trials of these projects.

            Lead Product(s): CV7301

            Therapeutic Area: Infections and Infectious Diseases Product Name: CV7301

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: GSK

            Deal Size: $1,100.0 million Upfront Cash: $147.1 million

            Deal Type: Collaboration July 20, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY